Pratik Shah - 09 Dec 2025 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role: President, CEO and Chairperson, Director
Signature: /s/ Mustapha Parekh, Attorney-in-Fact
Issuer symbol: DSGN
Transactions as of: 09 Dec 2025
Transactions value $: $0
Form type: 4
Filing time: 11 Dec 2025, 16:30:27 UTC
Previous filing: 14 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shah Pratik	President, CEO and Chairperson, Director	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD	/s/ Mustapha Parekh, Attorney-in-Fact	11 Dec 2025	0001580787

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DSGN	Stock option (right to buy)	Award	$0	+525K		$0.00	525K	09 Dec 2025	Common Stock	525K	$2.48	Direct	F1
transaction	DSGN	Stock option (right to buy)	Award	$0	+525K		$0.00	525K	09 Dec 2025	Common Stock	525K	$2.48	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 1, 2023, the Reporting Person was granted an option to purchase 525,000 shares of common stock. 25% of the shares subject to the option would vest on August 25, 2024, and thereafter the balance would vest in equal monthly installments over the following 36 months, provided that, as an additional condition, no shares under the option would vest until the Issuer achieved a specific performance condition. On December 9, 2025, the Issuer's Board of Directors deemed that the performance condition had been met, resulting in vesting of the option as to 295,312 shares. The remainder of the unvested shares subject to the option shall vest monthly through August 25, 2027 subject to the continuous service of the Reporting Person through each such date.

Content

On September 1, 2023, the Reporting Person was granted an option to purchase 525,000 shares of common stock. 25% of the shares subject to the option would vest on August 25, 2024, and thereafter the balance would vest in equal monthly installments over the following 36 months, provided that, as an additional condition, no shares under the option would vest until the Issuer achieved a specific performance condition. On December 9, 2025, the Issuer's Board of Directors deemed that the performance condition had been met, resulting in vesting of the option as to 295,312 shares. The remainder of the unvested shares subject to the option shall vest monthly through August 25, 2027 subject to the continuous service of the Reporting Person through each such date.